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Background: Convincing data on epidermal growth factor receptor
(EGFR) mutations in Chinese patients with non-small-cell lung
cancer (NSCLC) remain limited. We investigated the relevance of
demographic characteristics and EGFR mutations, correlations be-
tween the efficacy of gefitinib and EGFR mutations in NSCLC, and
to identify individuals who would likely benefit from gefitinib.
Methods: We conducted a meta-analysis based on updated individ-
ual patient data from six medical centers in mainland China. Out-
come measures included the EGFR mutation status, demographic
characteristics, response, and survival.
Results: Among 506 patients with NSCLC who received EGFR
mutation analysis, the EGFR mutation rate was 30.04%. Patients
with adenocarcinoma had a higher mutation rate than those with
non-adenocarcinoma (44.1% vs 9.2%; p  0.00001). The EGFR
mutation rate for smokers was 15.1%, lower than that for non-
smokers (45.5%) (p 0.00001). Male patients had a lower mutation
rate than female patients (23.1% vs 42.9%; p  0.0001). Multivar-
iate analysis showed that “adenocarcinoma” and “non-smoker” were
independent predictors of EGFR mutations. In a subgroup of 57
patients with complete treatment data, the response rate to gefitinib
in the EGFR mutant group was 60.7%, significantly higher than that
in the wild-type EGFR group (17.2%) (odds ratio, 5.78; 95% CI,
1.95–17.13; p  0.002). “EGFR mutation”, “adenocarcinoma,” and
“non-smoker” were independent predictors of response. Overall
survival in the EGFR mutant group and the wild-type group did not
differ significantly (hazard ratio, 0.60; 95% CI, 0.32–1.12; p 
0.110). “Adenocarcinoma status” was an independent prognostic
factor for survival.
Conclusions: In mainland China, “adenocarcinoma” and “non-
smoker” are independent predictors for EGFR mutations. Response
to gefitinib favors patients with EGFR mutations. The clinical
selected populations for gefitinib are non-smokers with adenocarci-
noma.
Key Words: Protein kinase inhibitors, Receptor, Epidermal growth
factor, Carcinoma, Non-small cell lung, Meta-analysis, Chinese.
(J Thorac Oncol. 2007;2: 430–439)
Lung cancer is the leading cause of cancer deaths in Chinaand worldwide. It is estimated that, per 100,000 Chinese
individuals, approximately 41.8 men and 19.3 women died
from lung cancer in 2005.1 Non-small-cell lung cancer
(NSCLC) accounts for approximately 85%.2 Despite treat-
ment advances, chemotherapy is only marginally effective in
most advanced cases.3,4 For those patients refractory to or
intolerant of the current chemotherapy, treatment options are
limited. Hence, more effective therapy with fewer side effects
is needed.
The epidermal-growth-factor receptor (EGFR) tyrosine-
kinase (TK) forms a part of the signaling pathway that regulates
tumor-cell proliferation, invasion, angiogenesis, metastasis, and
apoptosis.5 Because EGFR is often over-expressed in NSCLC
and the level of EGFR expression correlates with poor progno-
sis, EGFR inhibitors have been developed as novel therapy for
NSCLC.6,7 Gefitinib, the first molecular targeted agent approved
for the treatment of advanced NSCLC, is a highly effective
EGFR TK inhibitor (TKI) that selectively blocks the signal
transduction pathways implicated in cancer growth.8,9
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In 2004, Lynch et al. and Paez et al. reported almost
simultaneously that mutations of EGFR may predict the
sensitivity of NSCLC to gefitinib,10,11 which is regarded as a
milestone for approaching individualized molecular targeted
therapy for NSCLC. Subsequently, many publications have
reported data consistent with this finding. Phase II trials with
EGFR-TKI in patients with chemorefractory NSCLC have
found response rates of 9% to 19% and median survival
ranging from 7.6 to 8.4 months.8,9,12 Furthermore, BR21, a
phase III study of erlotinib, showed a significant survival
benefit compared with placebo.13 However, in a similarly
designed study, ISEL, gefitinib did not show any survival
gain over placebo. Subsets of patients who had never smoked
and were of Asian origin seemed to benefit from gefitinib.14
Whether gefitinib is less efficacious than erlotinib or whether
the study design, the patients enrolled, the tumor molecular
characteristics, and the dose might have contributed to the
different outcome remain unclear.15 One area of current
research focuses on the identification of factors distinguishing
those who are more likely to derive benefit from EGFR-TKIs
therapy, this information could then aid in patient selection.
Based on population, China is the largest country in the
world, with a population of approximately 1.3 billion at the
end of 2004. However, to date, data on EGFR mutations in
mainland China are scarce. Comprehensive review of exist-
ing information regarding EGFR mutations is essential for
personalized therapy for advanced NSCLC.
The gold standard for combining evidence from trials is
individual patient data meta-analysis (IPD-MA), in which
updated data from each relevant trial are centrally collected,
processed, and analyzed.16 In this report, we include all
relevant trials from a comprehensive search to provide evi-
dence on the relationship between EGFR mutations and
gefitinib therapy for patients with NSCLC from mainland
China.
MATERIALS AND METHODS
Selection Criteria
Both published and unpublished trials that match the
criteria below were eligible. We included cohort studies on
EGFR mutations in NSCLC. Individuals with histologically
confirmed NSCLC were study participants. In refractory
NSCLC with performance status (PS) of 0 to 2, tissue
samples were taken and the EGFR mutation analyses were
performed; 250 mg gefitinib was taken once daily uninter-
rupted until disease progression or intolerable toxicity. The
EGFR mutation status, demographic characteristics of pathol-
ogy, gender, age, smoking history and TNM stage, response,
and survival were outcome measures. Any patients that were
not from mainland China, patients with small cell lung
cancer, and patients who lacked the IPD were excluded.
Search Strategy
Both published and unpublished studies were included.
A systematic search was used to identify all relevant trials
from January 2000 to June 2006. Computerized bibliographic
searches with PubMed, EMBASE, Cochrance Library, Chi-
nese biomedical literature database, and www.clinicaltrials.
gov were supplemented with hand searches of conferences
abstracts and specialty journals. Articles were identified by
use of the related-articles function in PubMed. References of
articles identified were also searched manually. All investi-
gators who took part in the meta-analysis were asked to
identify trials.17 We eventually included six clinical trials that
explored the role of EGFR mutations in NSCLC in mainland
China. Four of these trials, conducted by Guangdong Provin-
cial People’s Hospital (GDPPH), Peking Union Medical Col-
lege Hospital (PKUMCH), Sun Yat-sen University (SYSU),
and Shanghai Pulmonary Hospital (SHPH) were reported at
the 2005 ASCO annual meeting.18–21 Fourteen published
articles from 11 institutions were detected through electronic
searches. Among these, two trials were excluded for lacking
the IPD,22,23 and seven were excluded because the data were
generated outside mainland China (Hong Kong, Taiwan,
Canada, Spain, and the United States). The remaining two
trials24–28 came from the same studies conducted by
PKUMCH and SYSU presented at the 2005 ASCO annual
meeting. Finally, 506 individuals from the above four trials
and two other unpublished trials directed by Jilin University
(JLU) and the Second Shanghai Medical College (SSHMC)
through cooperation were included.
Data Collection
The Secretariat decided what data to collect. IPD were
obtained directly from the responsible investigator in all
eligible trials. Updated information on demographic charac-
teristics, EGFR mutations, and efficacy of therapy were
collected, sent to the central coordination center, and re-
viewed for consistency and completeness before analysis. All
data were thoroughly checked and extracted by two reviewers
independently; any queries were resolved by discussion to
validate the accuracy of extraction.29 The last follow-up date
was February 14, 2006.
EGFR Mutation Analysis
The mutation analysis of the EGFR-TK domain was
performed with frozen or paraffin-embedded tumor tissues.
Tumor samples were obtained from thoracotomy in early-
stage NSCLC, diagnostic procedures such as fiberbrochos-
copy and transthoracic needle aspiration biopsy in advanced
cases. Genomic DNA was extracted from specimens, and
exons 18, 19, 20, and 21 were amplified with four pairs of
primers. Uncloned PCR fragments were sequenced and ana-
lyzed in both sense and antisense directions. Both forward
and reverse sequencing reactions were performed with the
respective primers and the ABI (Applied Biosystems, Foster
City, CA) company Big Dye Terminator v3.1 Cycle Sequencing
Kit. Sequencing products were electrophoresed on an ABI3700
genetic analyzer. All sequence variations were confirmed by
multiple independent PCR amplifications and repeated sequenc-
ing reactions.10 EGFR mutations were analyzed using direct
sequencing in all the six institutions included.
Assessment of Efficacy
Baseline evaluation included chest and upper abdomen
computed tomography including adrenals, brain magnetic
resonance imaging, and bone scan within 14 days before
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entry. Patients were re-evaluated at the end of the first and
third months of therapy, then every 3 months. Objective
tumor responses were assessed according to the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria.30
Overall survival (OS) was assessed from the first dose of
gefitinib to the date of death for any cause. Data for patients
who were alive at the time of follow-up were censored.
Efficacies were evaluated in the same procedure in the six
institutions included.
Statistical Analysis
The relationship between EGFR mutation and demo-
graphic characteristics was analyzed with IPD-MA and lo-
gistic regression. The data were input to RevMan 4.2 (down-
loaded from www.cochrane.org) under the IPD category fix
effect model, the pooled IPD Peto odds ratio (OR) and 95%
confidence interval (CI) were calculated. Analyses were
weighted by trial size.16 In logistic regression, univariate
analysis was first performed and combined with the indica-
tions of previous studies to identify the covariates for multi-
variate analyses. The binary logistic regression forward max-
imal likelihood ratio (LR) test was then performed to screen
the variables. The relationship between response and various
covariates were analyzed through IPD-MA and logistic re-
gression. Pearson 2 and subgroup analyses were used to
identify the subgroups that correlated best with response. In
survival analysis, the log-rank expected number of events and
variance were used to calculate the HR at the 95% CI for
individual trials and pooled across all trials using the method
of survival curve and hazard ratio plot (SCHARP) pro-
gram.31–33 Trials were grouped by mutation sites. Analyses
were weighted by trial variance. We used 2 to test for gross
statistical heterogeneity across all trials. The Kaplan-Meier
method was used to estimate the distribution of OS in
gefitinib-treated NSCLC stratified by mutation sites. The
absolute effects of treatment on median survival were read
from Kaplan-Meier curves. Multivariate Cox regression was
used to determine the prognostic factors. The statistical anal-
yses were performed using RevMan 4.2, SigmaPlot 10.0 with
SigmaStat 3.5 integration, and STATA 8.0. All p values were
two-sided, and p  0.05 was considered significant.
RESULTS
Patient Characteristics
As illustrated in Table 1, 506 patients with NSCLC
who were analyzed for EGFR mutations from six medical
centers in Guangzhou, Beijing, Shanghai, and Changchun
between 2002 and 2006 met the inclusion criteria. The overall
EGFR mutation rate was 30.04% in activating mutations of
exon 19 deletions and exon 21 L858R substitutions. Two
point mutations in exons 18 G719C, a T790M mutation
located in exon 20, and six other types of rare mutations in
exon 18 and 21 were excluded from the analysis. Full data,
including survival, response, and demography characteristics
of EGFR mutations, were only available for 57 patients from
GDPPH and PKUMCH. The efficacy data were not available
from the other four centers.
Relationship Between EGFR Mutations and
Patient Characteristics
In meta-analysis, we chose 0.01 to 100 as the logarith-
mic scale (Figure 1). For the comparison between adenocar-
cinoma and non-adenocarcinoma, JLU’s study was excluded
because all their cases were adenocarcinoma. All the other
five centers reported a significant result except SYSU. Over-
all, patients with adenocarcinoma had a significantly higher
EGFR mutation rate (44.1%) than those without adenocarci-
noma (9.2%). The pooled IPD Peto OR and 95% CI was 5.41
(3.57–8.22) (p  0.00001) (Figure 1A).
Men had a lower EGFR mutation rate (23.1%) than
women (42.9%), with the Peto OR and 95% CI being 0.42
(0.28–0.63) (p  0.0001). Differences in data from four of
the six centers reached statistical significance. (Figure 1B).
The data from PKUMCH lacked information about
smoking history, except for 30 patients who received ge-
fitinib. The comparison between smokers and non-smokers
from each center showed a tendency to favor the non-
smokers, whereas only four reached significant difference.
Smokers had a lower EGFR mutation rate (15.1%) than
non-smokers (45.5%), with the Peto OR and 95% CI being
0.24 (016–0.36) (p  0.00001). (Figure 1C).
Univariate analysis was first performed to select covari-
ates for subsequent multivariate analysis. The dependent
variable was EGFR mutation status (mutant and wild-type).
The candidate covariate included institution (GDPPH,
PKUMCH, SYSU, SHPH, JLU, and SHMC), age (years),
TNM stage (I, II, III, and IV), adenocarcinoma status (ade-
nocarcinoma and non-adenocarcinoma), histology (adenocar-
cinoma, squamous, large cell, and adenosquamous), smoking
history (smoker and non-smoker), smoke index (pack-years),
and gender (male and female). Institution and histology were
categorical variables. Institution (p  0.074, 0.153, 0.560,
0.096, 0.214, and 0.628, respectively), age (p  0.446), and
TNM (p 0.502) were excluded because their value was p
0.05 and there were no previous studies indications. Among
the five variables screened by multivariate analysis, adeno-
carcinoma status (OR  3.66; 95%CI, 1.89–7.07; p 
0.00001) and smoking history (OR  0.38; 95%CI, 0.22–
0.66; p  0.00001) stayed in the model using binary logistic
regression with forward maximal LR test.
Response to Gefitinib
The analyses were based on data for 57 patients with
NSCLC from two institutions. The dependent variable was
response (complete response [CR]  partial response [PR]
and stable disease [SD]  progressive disease [PD]). The
candidate variables included institution (GDPPH and
PKUMCH) (p  0.088), EGFR mutation status (mutant and
wild-type) (p  0.001), adenocarcinoma status (adenocarci-
noma and non-adenocarcinoma) (p  0.01), smoking history
(smoker and non-smoker) (p  0.003), and gender (male and
female) (p  0.02). All five variables were selected for the
multivariate analysis based on previous study indications.
Among them, adenocarcinoma status (p  0.998), smoking
history (p  0.039), and EGFR mutation status (p  0.006)
continued in the model.
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In meta-analysis, both centers had a tendency to favor
EGFR mutation group in response, and the IPD Peto OR and
95% CI was 5.78 (1.95–17.13) (p 0.002). The response rate
in the EGFR mutation group (60.7%, 17 of 28) was signifi-
cantly higher than that of the EGFR wild-type group (17.2%,
5 of 29) (Figure 2A).
The overall response rate to gefitinib was 38.6 % (22 of
57); the EGFR mutation rate was 49.12% (28 of 57) in this
subset. The response rate in subgroup of adenocarcinoma 
non-smoker (60.0%) or adenocarcinoma  non-smoker 
female (60.9%) was similar to that of the mutation group
(60.7%); p  0.956 and p  0.991, respectively. The sub-
group analyses showed that response rate favored the follow-
ing six combinations with the overall effect Z value and p
values as follows: ANSEM (Z  3.97, p  0.0001),
ANS (Z  3.52, p  0.0004), EMANSF (Z  3.14,
p  0.002), ANSF (Z  2.94, p  0.003), NSF (Z 
2.77, p  0.006), and FA (Z  2.65, p  0.008). The
combined subgroup of ANSEM had the highest response
rate of 76.5 % (13 of 17). (Figure 2B).
Survival
Analyses were based on IPD from 57 patients in two
trials (GDPPH and PKUMCH) using SCHARP program and
Kaplan-Meier method (Figure 3). The integration of data did
not show significantly longer survival in the EGFR mutation
TABLE 1. Patient characteristics
Institutions
Characteristics GDPPH PKUMCH SYSU SHPH JLU SHMC Total %
n 142 76 52 81 54 101 506 100
Age (yr)
Median 60 62.5 58 62 56.5 62.5 60
Range 24–84 34–83 36–76 39–83 32–76 39–81 24–84
Gender
Male 98 41 39 52 27 72 329 65.0
Female 44 35 13 29 27 29 177 35.0
Smoking history
Smoker 84 12a 33 41 18 63 251 55.6
Non-smoker 58 18a 19 40 36 38 209 44.4
Histology
Adenocarcinoma 80 36 24 38 54 41 273 61.7
Squamous cell 37 25 20 31 0 33 146 28.8
Adenosquamous 5 0 4 12 0 14 35 6.9
Large cell 10 0 0 0 0 3 13 2.6
Bronchioalveolarb 10 15 4 0 0 10 39 7.7
EGFR mutation statusc
Mutant 42 31 10 21 21 27 152 30.04
Wild-type 100 45 42 60 33 74 354 69.96
TNM stage
I 60 NA NA 34 21 30 145 38.4
II 22 NA NA 11 11 18 62 16.4
III 37 NA NA 31 17 29 114 30.1
IV 23 NA NA 5 5 24 57 15.1
Response to gefitinibd 27 30 NA NA NA NA 57 100
Complete response 3 0 NA NA NA NA 3 5.3
Partial response 10 9 NA NA NA NA 19 33.3
Stable disease 8 12 NA NA NA NA 20 35.1
Progressive disease 6 9 NA NA NA NA 15 26.3
Survival status 27 30 NA NA NA NA 57 100
Complete data 18 26 NA NA NA NA 44 77.2
Censor data 9 4 NA NA NA NA 13 22.8
Values are expressed as n of patients unless otherwise specified. EGFR, epidermal growth factor receptor; GDPPH, Guangdong
Provincial People’s Hospital; UMCH, Peking Union Medical College Hospital; SYSU, Sun Yat-sen University; SHPH, Shanghai Pulmonary
Hospital; JLU, Jilin University; SHMC, Second Shanghai Medical College; NA, not available.
a The data from PKUMCH lacked information about smoking history, except for 30 patients who received gefitinib therapy.
b Patients with bronchioalveolar carcinoma were included in the adenocarcinoma group for analysis.
c Two point mutations in exons 18 G719C, a T790M mutation located in exon 20 and other six types of rare mutations in exon 18 and
21 were excluded from analysis.
d RECIST criteria.
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group compared with the wild-type group (pooled HR for
death, 0.60; 95% CI, 0.32–1.12; p  0.110) with the absolute
difference of median survival 257 days versus 115 days
(Figure 3A); median survival was estimated to be 619 days
versus 140 days for exon 19 deletions group versus the
wild-type group (pooled HR, 0.59; 95% CI, 0.28–1.26;
p  0.172) (Figure 3B). The survival rates between the
exon 21 L858R substitutions group and the wild-type
group did not differ significantly (median survival 168 vs
182 days; pooled HR, 0.88; 95% CI, 0.45–1.74; p  0.723)
(Figure 3C). There was no evidence of gross statistical
heterogeneity within trials.
In Cox regression, univariate analysis was performed
first, followed by multivariate analysis. All the variables
defined were used in multivariate analyses based on the
indications of previously published studies regardless of their
FIGURE 1. Relationship between EGFR mutations and the patient characteristics. A, Patients with adenocarcinoma had a sig-
nificantly higher EGFR mutation rate (44.1%) than those without adenocarcinoma (9.2%). The pooled IPD Peto OR and 95%
CI was 5.41 (3.57-8.22) (p  0.00001). B, Men had a lower EGFR mutation rate (23.1%) than women (42.9%), with the Peto
OR and 95% CI being 0.42 (0.28–0.63) (p  0.0001). C, Smokers had a lower EGFR mutation rate (15.1%) than non-smok-
ers (45.5%), with the Peto OR and 95% CI being 0.24 (016–0.36) (p  0.00001).
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FIGURE 2. Relationship between EGFR mutations and response to gefitinib. A, The response rate in EGFR mutation group
(60.7%, 17 of 28) was significantly higher than that of EGFR wild-type group (17.2%, 5 of 29). The IPD Peto OR and 95% CI
was 5.78 (1.95–17.13) (p  0.002). B, The overall response rate to gefitinib was 38.6 % (22 of 57); the EGFR mutation rate
was 49.12 % (28 of 57) in this subset. The subgroup analyses showed that response rate favored all the following six combi-
nations with the overall effect Z value and p values as follows: FA (Z  2.65, p  0.008), NSF (Z  2.77, p  0.006),
ANS (Z  3.52, p  0.0004), ANSF (Z  2.94, p  0.003), ANSEM (Z  3.97, p  0.0001), and EMANSF
(Z  3.14, p  0.002).
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p values.34–37 The candidate covariates included EGFR mu-
tation status (p  0.076), gender (p  0.042), adenocarci-
noma status (p 0.00001), and smoking history (p 0.053).
Each variable was used in Cox regression for survival with
forward LR test to identify prognostic factors. The only
variable to stay was adenocarcinoma status (HR, 0.22;
95%CI, 0.10–0.45; p  0.00001).
DISCUSSION
It is now apparent that only subsets of patients are
responsive to EGFR-TKI. Gefitinib causes significant tumor
shrinkage in only approximately 10% of Caucasian patients
with NSCLC. Lynch et al. and Paez et al. similarly reported
that mutations of the EGFR gene, which cluster near the ATP
cleft of the TK domain, may predict sensitivity of NSCLC to
gefitinib.10,11 The mutations are also more common in pa-
tients who are Asian, female, non-smokers, and who have
adenocarcinoma38–42—all characteristics linked to the known
clinical predictors of gefitinib sensitivity.34–37
The present report is an IPD-MA elucidating the role of
EGFR mutations in NSCLC in mainland China, which may
be helpful in targeting patients for better responses to ge-
FIGURE 3. Kaplan-Meier plot of overall survival derived from IPD of GDPPH and PKUMCH. Data are grouped by exon muta-
tion sites.
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fitinib. The EGFR mutation rate in our study was 30.04%.
Thus far, many studies have reported mutational analyses for
the TK domain in thousands of patients with NSCLC. Chan
et al. reported that the overall mutation rate in unselected
cases of NSCLC was 16.7% but differed widely among
various race: patients of Asian origin have a higher preva-
lence compared with Caucasians (30.6% vs 7.6%, p 
0.0001).43 In this research, the EGFR mutation rate was
higher in women, non-smokers, and patients with adenocar-
cinoma, but only adenocarcinoma and non-smoker were in-
dependent factors linked to EGFR mutations. Our findings
are consistent with those of previous reports in different
Caucasians and Asian ethnicities.39–42,44,45 Otherwise, a se-
lection bias of gefitinib-treated patients, which accounted for
11% of total cases, may have contributed to the higher
frequency of EGFR-TKI mutations in our study. Further-
more, we observed that adenocarcinoma is a better predictor
for mutations than non-smoker, as the OR for mutations was
higher in adenocarcinoma. This may arise from the correla-
tion between lung cancer and smoking, as well as the lifestyle
pattern of Chinese. The relationship between smoking and
adenocarcinoma is not as strong as its relationship to squa-
mous carcinoma. Most adenocarcinomas may not be caused
by smoking, but genetic instability contributes to the devel-
opment of EGFR mutations. A variety of factors may lead to
an underlying gene alteration, including exposure to other
carcinogens such as radiation or second-hand smoke.46 More-
over, in contrast to their Western counterparts, 92% to 96% of
Chinese women have never smoked cigarettes in their life-
time. Among the women with lung cancer, 83% do not have
smoking history.47 Therefore, both female gender and non-
smoker status may be confounding factors for predicting
EGFR mutations. Adenocarcinoma should be used as the
prior clinical predictor for EGFR mutation. The secondary
predictor may be smoking history. Pham et al. reported that
the likelihood of EGFR mutations in exons 19 and 21 de-
creased as pack-years increased. Mutations were less com-
mon in patients who smoked for more than 15 pack-years or
who stopped smoking less than 25 years ago. Thus, TKI
therapy should not be limited to never-smokers, but expanded
to former smokers with exposures of less than 15 pack-years
or who are more than 25 years smoke-free.48 Because insti-
tution is not a correlating factor, there may be no difference
among several origins in China conferring EGFR mutations
in NSCLC.
The correlation between the efficacies of TKI therapy
and EGFR mutations in NSCLC is an area of interest.
Because, in our analysis, only 57 patients received gefitinib
therapy, efficacy data are limited and might lead to a selection
bias. Nevertheless, research based on IPD is beneficial. A
pooled IPD-MA could correct for some bias. Investigators
could be contacted for additional information, which allowed
for better compliance with regard to missing data and a more
balanced interpretation of the results and subgroup analy-
ses.16 In this study, adenocarcinoma, non-smoker, and EGFR
mutations were key factors that influenced response. The
response rate in the EGFR mutation group was 60.7%.
Mutation is a better predictor than gender, smoking, or
pathology alone. When any two clinical factors combined,
there was still no significant advantage compared with EGFR
mutation alone. Exclusively, adenocarcinoma  non-smoker
(60.0%) approached 60.7%. The highest response rate
(76.5%) was seen for EGFR mutation  adenocarcinoma 
non-smoker. The independent predictors for response in mul-
tivariate analysis, comparison of the response in various
combinations, and the overall effect in the subgroup analyses
provide evidence to choose non-smokers with adenocarci-
noma as the selected population for TKI in mainland China.
Conversely, we tentatively suggest that screening for muta-
tions should only apply to patients within the male smoker
non-adenocarcinoma category and patients with poor PS
when first-line EGFR-TKI therapy is considered in clinical
practice. According to our study, the response rate is lower
than the EGFR mutation rate in the subgroup of gefitinib-
treated patients. Although most patients developing PD pos-
sess wild-type EGFR and patients responsive to gefitinib are
more likely to harbor mutations, some patients carrying
mutations still have PD after TKI treatment. The presence of
EGFR mutations only partially correlates with tumor re-
sponse. Therefore, because not all responders carry muta-
tions, there are probably alternative mechanisms conferring
sensitivity to TKI therapy.
Although multiple retrospective studies reported that
EGFR mutations are linked to better survival in gefitinib-
treated patients with NSCLC,36,39,49–51 retrospective molecu-
lar subgroup analyses of the prospective BR.21 trial failed to
associate EGFR mutations with improved overall survival in
erlotinib.52 In our study, although the pooled analysis of HR
for the 57 gefitinib-treated patients with NSCLC showed no
significant difference between the EGFR mutation group and
the wild-type group, the exon 19 mutation group had a
tendency toward longer survival than the wild-type group. In
contrast, the exon 21 wild-type group had a trend for longer
survival compared with the mutation group. Two small-
sample studies also reported that patients with exon 19
deletions had longer survival after EGFR-TKI therapy com-
pared with those with L858R mutation. Prospective trials
with greater numbers of patients are needed to further define
the prognostic roles of different EGFR mutations with respect
to EGFR-TKI.53,54 The different distribution in the survival
curve between mutation sites may explain why some patients
with NSCLC with EGFR mutations gained favorable efficacy
but others did not, suggesting differences in activating EGFR
signaling by each mutation. The absence of statistical heter-
ogeneity among the trials indicated that there may be no
difference in survival after TKI therapy between GDPPH and
PKUMCH. Among the four variables that may help in patient
selection in the Cox regression, adenocarcinoma status may
be considered an independent prognostic factor. In the ISEL
study, median survival did not differ significantly between
gefitinib and placebo in patients with adenocarcinoma in the
overall participant population,14 whereas subset analysis of
patients of Asian origin and earlier experience from Korea
both indicated that survival benefit was associated with ade-
nocarcinoma and smoking history.38,55 Considering the small
sample sizes in our study, our conclusions are not definitive.
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In mainland China, adenocarcinomas, non-smokers,
and women with NSCLC have a higher EGFR mutation rate.
Adenocarcinoma and non-smoker status, however, are inde-
pendent predictors for the EGFR mutations. There may be
little difference among several origins in mainland China
conferring EGFR mutations. The response to TKI favors
patients with EGFR mutations. The selected population for
gefitinib may be non-smokers with adenocarcinoma. Al-
though patients with a good response to TKI have longer
survival, it is unclear why the EGFR mutations predict
response but not survival. This may be the result of the
limited sample in our study. Further efforts should be made to
obtain data on survival from prospective translational trials in
combination with the tissue sample analysis to predict clinical
efficacy in EGFR-TKI therapy.
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